VAN WIJMEERSCH, Bart

Full Name
VAN WIJMEERSCH, Bart
Email
bart.vanwijmeersch@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Results 101-120 of 207 (Search time: 0.005 seconds).

Issue DateTitleContributor(s)TypeCat.
1012020Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmtsWiendl, H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wuerfel, J.; Buffels, R.; Kadner, K.; Kuenzel, T.; Vermersch, P.Journal ContributionM
1022020Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumabWiendl, Heinz; Carraro, Matthew; Comi, Giancarlo; Izquierdo, Guillermo; Kim, Ho Jin; Sharrack, Basil; Tornatore, Carlo; Daizadeh, Nadia; Chung, Luke; Jacobs, Alan K.; Hogan, Richard J.; Wychowski, Linda V.; VAN WIJMEERSCH, BartJournal ContributionA1
1032020Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension StudyZiemssen, Tjalf; Bass, Ann D.; Berkovich, Regina; Comi, Giancarlo; Eichau, Sara; Hobart, Jeremy; Hunter, Samuel F.; LaGanke, Christopher; Limmroth, Volker; Pelletier, Daniel; Pozzilli, Carlo; Schippling, Sven; Sousa, Livia; Traboulsee, Anthony; Uitdehaag, Bernard M. J.; VAN WIJMEERSCH, Bart; Choudhry, Zia; Daizadeh, Nadia; Singer, Barry A.Journal ContributionA1
1042020Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)Hartung, H-P; Comi, G.; Arnold, D. L.; Boyko, A. N.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, BartJournal ContributionM
1052020Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)Ziemssen, T.; Bass, A. D.; Berkovich, R.; Eichau, S.; Hobart, J.; Hunter, S. F.; Limmroth, V.; Pelletier, D.; Pozzilli, C.; Schippling, S.; Singer, B. A.; Sousa, L.; Traboulsee, A.; Uittlehaag, B. M. J.; VAN WIJMEERSCH, Bart; Poole, E. M.; Choudhry, Z.; Geertsen, S.; Daizadeh, N.; Comi, G.Journal ContributionM
1062020One-Year Interim Analysis of Health-Related Quality of Life in RRMS Patients Treated With Alemtuzumab in a Real-world Clinical Setting (LemQoL Study)VAN WIJMEERSCH, Bart; Harrower, T.; Hobart, J.; Kizlaitiene, R.; Marfia, G. A.; Patti, F.; Pearson, O. R.; Van Pesch, V.; Vanderdonckt, P.; Vecsei, L.; Shor, S.; Achiron, A.Journal ContributionM
1072020Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)Vermersch, P.; Eralinna, J.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Wei, W.; Comi, G.Journal ContributionM
1082020Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and managementCuker, Adam; Bass, Ann D.; Nadj, Congor; Agius, Mark A.; Steingo, Brian; Selmaj, Krzysztof W.; Thoits, Timothy; Guerreiro, Alexandre; VAN WIJMEERSCH, Bart; Ziemssen, Tjalf; Meuth, Sven G.; LaGanke, Christopher C.; Thangavelu, Karthinathan; Rodriguez, Claudio E.; Baker, Darren P.; Margolin, David H.; Jannsens, AnnJournal ContributionA1
92020Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studiesVAN WIJMEERSCH, Bart; Singer, Barry A.; Boster, Aaron; Broadley, Simon; Fernandez, Oscar; Freedman, Mark S.; Izquierdo, Guillermo; Lycke, Jan; Pozzilli, Carlo; Sharrack, Basil; Steingo, Brian; Wiendl, Heinz; Wray, Sibyl; Ziemssen, Tjalf; Chung, Luke; Margolin, David H.; Thangavelu, Karthinathan; Vermersch, PatrickJournal ContributionA1
102020Risk of secondary progressive multiple sclerosis: A longitudinal studyFambiatos, Adam; Jokubaitis, Vilija; Horakova, Dana; Havrdova, Eva Kubala; Trojano, Maria; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Lugaresi, Alessandra; Izquierdo, Guillermo; Grand'Maison, Francois; Grammond, Pierre; Sola, Patrizia; Ferraro, Diana; Alroughani, Raed; Terzi, Murat; Hupperts, Raymond; Boz, Cavit; Lechner-Scott, Jeannette; Pucci, Eugenio; Bergamaschi, Roberto; Van Pesch, Vincent; Ozakbas, Serkan; Granella, Franco; Turkoglu, Recai; Iuliano, Gerardo; Spitaleri, Daniele; McCombe, Pamela; Solaro, Claudio; Slee, Mark; Ampapa, Radek; Soysal, Aysun; Petersen, Thor; Sanchez-Menoyo, Jose Luis; Verheul, Freek; Prevost, Julie; Sidhom, Youssef; VAN WIJMEERSCH, Bart; Vucic, Steve; Cristiano, Edgardo; Saladino, Maria Laura; Deri, Norma; Barnett, Michael; Olascoaga, Javier; Moore, Fraser; Skibina, Olga; Gray, Orla; Fragoso, Yara; Yamout, Bassem; Shaw, Cameron; Singhal, Bhim; Shuey, Neil; Hodgkinson, Suzanne; Altintas, Ayse; Al-Harbi, Talal; Csepany, Tunde; Taylor, Bruce; Hughes, Jordana; Jun, Jae-Kwan; van der Walt, Anneke; Spelman, Tim; Butzkueven, Helmut; Kalincik, TomasJournal ContributionA1
112019Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosisSHARMIN, Sohely; Lefort, M.; Andersen, J.; Horakova, D.; Havrdova, E. K.; Alroughani, R.; Izquierdo, G.; Eichau, S.; Ozakbas, S.; Butzkueven, H.; Patti, F.; Onofrj, M.; Lugaresi, A.; Terzi, M.; Grammond, P.; Grand'Maison, F.; Yamout, B.; Prat, A.; Girard, M.; Duquette, P.; Boz, C.; Trojano, M.; McCombe, P.; Slee, M.; Lechner-Scott, J.; Turkoglu, R.; Sola, P.; Ferraro, D.; Granella, F.; Shaygannejad, V.; Prevost, J.; Skibina, O.; Solaro, C.; Karabudak, R.; VAN WIJMEERSCH, Bart; Csepany, T.; Spitaleri, D.; Vucic, S.; Leray, E.; Sorensen, P. S.; Sellebjerg, F.; Magyari, M.; Vukusic, S.; Kalincik, T.Journal ContributionM
122019Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical SettingsBarclay, Krista; Carruthers, Robert; Traboulsee, Anthony; Bass, Ann D.; LaGanke, Christopher; Bertolotto, Antonio; Boster, Aaron; Celius, Elisabeth G.; de Seze, Jerome; Dela Cruz, Dionisio; Habek, Mario; Lee, Jong-Mi; Limmroth, Volker; Meuth, Sven G.; Oreja-Guevara, Celia; Pagnotta, Patricia; Vos, Cindy; Ziemssen, Tjalf; Baker, Darren P.; VAN WIJMEERSCH, BartJournal ContributionA1
132019Therapeutic lag in relapsing multiple sclerosisROOSEN, Inge; Frascoli, F.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Eichau, S.; Patti, F.; Onofr, M.; Lugaresi, A.; Prat, A.; Girard, M.; Duquette, P.; Ozakbas, S.; Grammond, P.; Sola, P.; Ferraro, D.; Bergamaschi, R.; Boz, C.; Cartechini, E.; Sa, M. J.; Terzi, M.; Alroughani, R.; Grand'Maison, F.; Granella, F.; Iuliano, G.; Hupperts, R.; Lechner-Scott, J.; Spitaleri, D.; Van Pesch, V.; Soysal, A.; Prevost, J.; Aguera-Morales, E.; Olascoaga, J.; Turkoglu, R.; Sidhom, Y.; Gouider, R.; VAN WIJMEERSCH, Bart; Butzkueven, H.; Malpas, C.; Kalincik, T.Journal ContributionM
142019Predicting long-term sustained disability progression in multiple sclerosisSHARMIN, Sohely; Malpas, C.; Horakova, D.; Havrdova, E. K.; Izquierdo, G.; Eichau, S.; Trojano, M.; Prat, A.; Girard, M.; Duquette, P.; Onofrj, M.; Lugaresi, A.; Grand'Maison, F.; Grammond, P.; Sola, P.; Ferraro, D.; Terzi, M.; Hupperts, R.; Alroughani, R.; Boz, C.; Shaygannejad, V.; Van Pesch, V.; Cartechini, E.; Kappos, L.; Lechner-Scott, J.; Bergamaschi, R.; Turkoglu, R.; Solaro, C.; Ramo-Tello, C.; Iuliano, G.; Granella, F.; VAN WIJMEERSCH, Bart; Spitaleri, D.; Bolanos, R. F.; Slee, M.; McCombe, P.; Prevost, J.; Ampapa, R.; Ozakbas, S.; Sanchez-Menoyo, J. L.; Soysal, A.; Vucic, S.; Petersen, T.; Verheul, F.; Butler, E.; Hodgkinson, S.; Sidhom, Y.; Gouider, R.; Butzkueven, H.; Kalincik, T.Journal ContributionM
152019Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)Vermersch, P.; Eralinna, J. -P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuhelj, R.; Wei, W.; Comi, G.Journal ContributionM
162019Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study)Montalban, X.; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M.; Lycke, J.; Massacesi, L.; Naismith, R. T.; Nakamura, K.; Pandey, K.; Schippling, S.; Vermersch, P.; Wiendl, H.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, BartJournal ContributionM
172019IgD(-)CD27(-) double negative B cells of multiple sclerosis patients have a pro-inflammatory migratory phenotype and functionBECKERS, Lien; Diaz, G. Montes; Villar, L. M.; VAN WIJMEERSCH, Bart; SOMERS, Veerle; FRAUSSEN, JudithJournal ContributionM
182019Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapiesVAN WIJMEERSCH, Bart; Buffels, R.; Clinch, S.; Kuhelj, R.; Wei, W.; Vermersch, P.Journal ContributionM
192019Deciphering morphology of Evoked PotentialsYPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; HELLINGS, Niels; Cambron, M.; Dive, D.; Laureys, G.; POPESCU, Veronica; VAN WIJMEERSCH, Bart; PEETERS, LiesbetJournal ContributionM
202019Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progressionDE BROUWER, Edward; PEETERS, Liesbet; BECKER, Thijs; Altintas, A.; Soysal, A.; VAN WIJMEERSCH, Bart; Boz, C.; Oreja-Guevara, C.; Gobbi, C.; Solaro, C.; Ramo, C.; Spitaleri, D. L.; Maimone, D.; Aguera-Morales, E.; Cartechini, E.; Butler, E.; Havrdova, E.; Patti, F.; Granella, F.; Grand'Maison, F.; Moore, F.; Verheul, F.; Luliano, G.; Butzkueven, H.; Lechner-Scott, J.; Kuhle, J.; Sanchez Menoyo, J. L.; Rojas, J. I.; Prevost, J.; Onofrj, M.; Rio, M. E.; Sa, M. J.; Saladino, M. L.; Slee, M.; Barnett, M.; Terzi, M.; Deri, N.; McCombe, P.; Sola, P.; Duquette, P.; Grammond, P.; Ampapa, R.; Alroughani, R.; Hupperts, R.; Turkoglu, R.; Gouider, R.; Fernandez Bolanos, R.; Bergamaschi, R.; Kalincik, T.; Moreau, Y.Journal ContributionM